Vasomotor Symptoms - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The vasomotor symptoms market was valued at USD 4.2 billion in 2025 and estimated to grow from USD 4.5 billion in 2026 to reach USD 6.4 billion by 2031, at a CAGR of 7.4% during the forecast period 2026-2031. This report is Segmented by Treatment Type (Hormonal, Non-Hormonal), Route of Administration (Oral, Transdermal Patch, Transdermal Gel and Spray, Parenteral, Topical), Distribution Channel (Hospital, Retail, Online Pharmacies), Menopausal Stage (Perimenopause, Early and Late Post-Menopause), and Geography (North America, Europe, APAC, MEA, South America). The Market Forecasts are in Value (USD).

Global Vasomotor Symptoms Market Trends and Insights

Rise in Post-Menopausal Female Population Base

The vasomotor symptoms market continues to benefit from a large and durable demographic base that keeps new patients entering treatment consideration every year. More than 1 billion women were in their postmenopausal years in 2025, and the World Health Organization expects that figure to reach 1.2 billion by 2030. The burden is not evenly distributed because a large share of postmenopausal women will live in lower and middle-income countries where treatment infrastructure remains thinner than in OECD markets. Since up to 80% of women experience vasomotor symptoms during the menopausal transition, population growth adds to an already under-treated pool rather than only widening a fully served market.

Growing Pharmaceutical Investment in Women's Health Portfolios

The vasomotor symptoms market is drawing more visible pharmaceutical attention as large companies deepen their women’s health focus through acquisitions, approvals, and late-stage development activity. Sun Pharmaceutical Industries announced in April 2026 that it would acquire Organon & Co. in a cash deal valued at USD 11.75 billion, bringing together a broad women’s health portfolio with global reach across more than 140 countries. Bayer expanded the commercial profile of elinzanetant through approvals in the UK, the United States, and the European Union during 2025, which shows sustained capital commitment to a new non-hormonal class. Astellas also moved fezolinetant forward in Japan in 2026 through a positive Phase 3 readout, which keeps the pipeline active across major regions rather than only in North America and Europe. This pattern matters for the vasomotor symptoms market because bigger portfolios usually bring stronger launch support, wider registration effort, and more consistent payer engagement.

Long-Term Hepatic Safety Concerns for NK-3 Antagonists

Safety monitoring remains one of the clearest near-term constraints on the vasomotor symptoms market because it directly affects prescribing comfort and patient follow-through. The FDA first issued a Drug Safety Communication on fezolinetant in September 2024 and then added a boxed warning in December 2024 after postmarketing reports of serious liver injury. The revised protocol requires baseline liver function testing, monthly testing for the first 3 months, and further testing at months 6 and 9, which adds a practical burden to routine use. The European Medicines Agency also issued a direct healthcare professional communication in 2025, showing that the monitoring issue is not limited to the United States. Even though elinzanetant showed a cleaner hepatic profile in the OASIS trials, prescriber confidence in the broader class will still depend on longer-term safety experience.

Other drivers and restraints analyzed in the detailed report include:

• Rapid Approvals of Neurokinin-3 Receptor Antagonists
• Employer Adoption of Menopause Benefits Platforms
• Expansion of Tele-Menopause Virtual Clinics in Underserved Regions
• AI-Enabled Precision Dosing and Companion Diagnostics
• Limited Reimbursement Outside OECD Markets
• Cultural Stigma Suppressing Care-Seeking in Asia and Middle East and Africa
• Regulatory Ambiguity for Botanical OTC Supplements

Segment Analysis

Hormonal treatment held 68.4% of vasomotor symptoms market share in 2025, which made it the largest revenue pool across treatment options. This position reflects long clinical use, broad physician familiarity, and strong evidence that menopausal hormone therapy can reduce vasomotor symptom frequency by as much as 75% versus placebo. Estrogen-only products serve women without a uterus, while combination estrogen-progesterone products remain central for women with an intact uterus, so prescribing patterns are shaped by standard risk screening and patient history. Hormonal therapy also benefits from established payer pathways in developed markets, which supports stable use in primary care and OB/GYN settings.

The vasomotor symptoms market size for non-hormonal treatment is projected to expand at 10.8% CAGR through 2031, making it the fastest-growing treatment group. This expansion is being driven mainly by NK-targeted therapies, especially fezolinetant from Astellas and elinzanetant from Bayer, which have given clinicians a new option for patients who cannot or do not want to use hormones. SSRIs and SNRIs still hold a practical role for women with hormone contraindications, although their use is more selective and their effect profile is less direct than targeted NK therapies. Herbal and dietary supplements remain the most fragmented corner of the vasomotor symptoms industry, and their growth is constrained by tighter rules on symptom claims and weaker product differentiation.

Oral delivery accounted for 56.5% of the vasomotor symptoms market in 2025, which kept it ahead of all other administration routes. This lead reflects the long-established role of oral hormone therapy and the fact that both approved NK-targeted therapies are taken orally once daily. Physician comfort with tablet-based regimens also supports oral continuity because titration, counseling, and refill behavior are already well understood in routine practice. The Asia-Pacific Menopause Federation’s 2025 consensus statement further noted that oral hormone therapy remains the most common format prescribed across the region.

Transdermal gel and spray formulations are projected to grow at 8.8% CAGR through 2031, which makes them the most dynamic route. Their appeal comes from bypassing first-pass hepatic metabolism, reducing thromboembolism risk relative to some oral options, and providing steadier hormone exposure in daily use. This route is especially relevant in a vasomotor symptoms market where liver monitoring has become more prominent around some non-hormonal agents, because clinicians may place higher value on cleaner delivery logic in the overall treatment plan. Patches, parenteral formats, and vaginal or topical routes remain important for narrower clinical needs, but they do not yet match the scale of oral use or the current momentum of transdermal innovation.

Complete Report Scope:

• By Treatment Type
  • Hormonal Treatment
    • Estrogen
    • Progesterone
    • Estrogen-Progesterone Combination
  • Non-Hormonal Treatment
    • NK-3 Receptor Antagonists
    • SSRIs
    • SNRIs
    • Gabapentinoids
    • Herbal and Dietary Supplements
• By Route of Administration
  • Oral
  • Transdermal Patch
  • Transdermal Gel and Spray
  • Parenteral, Injectable
  • Topical, Vaginal and Derma
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Menopausal Stage
  • Perimenopause
  • Early Post-Menopause, Less Than 5 Years
  • Late Post-Menopause, More Than 5 Years
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of APAC
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.9% of vasomotor symptoms market share in 2025, which made it the leading regional contributor. The region benefits from strong specialist access, early adoption of new therapies, and better-established reimbursement systems than most other markets. The FDA’s 2024 boxed warning on fezolinetant added monitoring complexity, but it also increased attention on class differentiation rather than stopping commercial interest in non-hormonal care. Employer-sponsored menopause programs from organizations such as Sun Life U.S. and CVS Health are also widening access beyond standard payer channels.

Europe remained the second-largest regional block and continues to be shaped by formal reimbursement reviews and regulatory milestones. Bayer reported that around 40% of women in Europe experience moderate to severe vasomotor symptoms based on data from the OASIS clinical program. The European Commission approved elinzanetant in November 2025 for both menopause-associated vasomotor symptoms and vasomotor symptoms related to endocrine therapy for breast cancer, which gave the region the broadest approved non-hormonal label in the category. NICE also required National Health Service funding for fezolinetant within 90 days for eligible patients, although reimbursement remains uneven across European countries and creates a two-speed access pattern.

The Asia-Pacific vasomotor symptoms market size is projected to grow at 10.5% CAGR through 2031, which makes it the fastest-growing regional segment. Japan remains a key country to watch because Astellas reported positive Phase 3 results for fezolinetant there in February 2026, supporting a future regulatory filing. Australia has also moved early with elinzanetant approval and expanded access through a fourth virtual menopause hub in New South Wales during 2026. At the same time, provider knowledge gaps in parts of Asia and persistent stigma in the Middle East and Africa continue to suppress diagnosis and treatment uptake. South America remains a smaller opportunity set, and future expansion there is likely to depend on stronger structured access pathways and broader women’s health engagement.

List of Companies Covered in this Report:

• Abbvie
• Astellas Pharma
• Bayer
• Besins Healthcare
• Cipla
• Eisai
• Endoceutics Inc.
• Ferring Pharmaceuticals
• Fervent Pharmaceuticals
• Hisamitsu Pharmaceutical Co.
• KaNDy Therapeutics
• Knight Therapeutics Inc.
• Lupin
• Mithra Pharmaceuticals
• Novo Nordisk
• Organon and Co.
• Pfizer
• Sun Pharma Industries Ltd.
• Teva Pharmaceutical Industries
• Theramex
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support